Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith R Abrams

Showing results (81-90 of 151) with videos related to

Pageof 16
Sort By:
Medical Care|August 4, 2009
Modeling the value for money of changing clinical practice change: a stochastic application in diabetes careTies Hoomans, Keith R Abrams, Andre J H A Ament, et al.
Statistics in Medicine|September 19, 2006
Evidence-based sample size calculations based upon updated meta-analysisAlexander J Sutton, Nicola J Cooper, David R Jones, et al.
Pharmacoeconomics|October 27, 2023
Transporting Comparative Effectiveness Evidence Between Countries: Considerations for Health Technology AssessmentsAlex J Turner, Cormac Sammon, Nick Latimer, et al.
BMC Public Health|September 27, 2022
Double-counting of populations in evidence synthesis in public health: a call for awareness and future methodological developmentHumaira Hussein, Clareece R Nevill, Anna Meffen, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|October 8, 2009
Meta-analysis of rare and adverse event dataAlexander J Sutton, Nicola J Cooper, Paul C Lambert, et al.
BMC Public Health|December 9, 2022
Publisher Correction: Double-counting of populations in evidence synthesis in public health: a call for awareness and future methodological developmentHumaira Hussein, Clareece R Nevill, Anna Mefen, et al.
Statistics in Medicine|May 28, 2019
Bivariate network meta-analysis for surrogate endpoint evaluationSylwia Bujkiewicz, Dan Jackson, John R Thompson, et al.
American Journal of Epidemiology|December 8, 2007
Recreational drug use: a major risk factor for gastroschisis?Elizabeth S Draper, Judith Rankin, Ann M Tonks, et al.
Pharmacoeconomics - Open|June 12, 2023
Cost-Effectiveness Analysis of Siltuximab for Australian Public Investment in the Rare Condition Idiopathic Multicentric Castleman DiseaseFrancis Shupo, Keith R Abrams, Zanfina Ademi, et al.
Statistica Neerlandica|January 3, 2020
Mixed-effects models for health care longitudinal data with an informative visiting process: A Monte Carlo simulation studyAlessandro Gasparini, Keith R Abrams, Jessica K Barrett, et al.
Pageof 16

Showing results (81-90 of 151) with videos related to

Sort By:
Pageof 16
Medical Care|August 4, 2009
Modeling the value for money of changing clinical practice change: a stochastic application in diabetes careTies Hoomans, Keith R Abrams, Andre J H A Ament, et al.
Statistics in Medicine|September 19, 2006
Evidence-based sample size calculations based upon updated meta-analysisAlexander J Sutton, Nicola J Cooper, David R Jones, et al.
Pharmacoeconomics|October 27, 2023
Transporting Comparative Effectiveness Evidence Between Countries: Considerations for Health Technology AssessmentsAlex J Turner, Cormac Sammon, Nick Latimer, et al.
BMC Public Health|September 27, 2022
Double-counting of populations in evidence synthesis in public health: a call for awareness and future methodological developmentHumaira Hussein, Clareece R Nevill, Anna Meffen, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|October 8, 2009
Meta-analysis of rare and adverse event dataAlexander J Sutton, Nicola J Cooper, Paul C Lambert, et al.
BMC Public Health|December 9, 2022
Publisher Correction: Double-counting of populations in evidence synthesis in public health: a call for awareness and future methodological developmentHumaira Hussein, Clareece R Nevill, Anna Mefen, et al.
Statistics in Medicine|May 28, 2019
Bivariate network meta-analysis for surrogate endpoint evaluationSylwia Bujkiewicz, Dan Jackson, John R Thompson, et al.
American Journal of Epidemiology|December 8, 2007
Recreational drug use: a major risk factor for gastroschisis?Elizabeth S Draper, Judith Rankin, Ann M Tonks, et al.
Pharmacoeconomics - Open|June 12, 2023
Cost-Effectiveness Analysis of Siltuximab for Australian Public Investment in the Rare Condition Idiopathic Multicentric Castleman DiseaseFrancis Shupo, Keith R Abrams, Zanfina Ademi, et al.
Statistica Neerlandica|January 3, 2020
Mixed-effects models for health care longitudinal data with an informative visiting process: A Monte Carlo simulation studyAlessandro Gasparini, Keith R Abrams, Jessica K Barrett, et al.
Pageof 16